

Remarks

Applicants elect, without traverse, Group III as defined in the pending application. Groups I and II as defined by the Examiner are the subject of the parent patent to this divisional application, United States Patent No. 6,620,833 to Greif et al.

Claim 7 has been rewritten in independent form as claim 8. Claims 9 -12 have been added to reflect the disclosure of active ingredients at page 18 of the application and the preferred species of benzimidazole set forth at page 5. Applicants respectfully traverse the requirement that the mixture comprise a single species. Searching the benzimidazoles has already been carried out in the parent application. Searching the combination of the claimed benzimidazoles and the limited additional ingredients set forth in the Markush groups in claims 8, 9 and 11 does not add a serious burden to the examination of the application. M.P.E.P. §§ 803, 803.02. As required by the restriction requirement, however, applicant elects the species set forth in claims 10 and 12 for examination.

Respectfully Submitted,

A handwritten signature in black ink, appearing to read "R. S. Bullitt", with a stylized flourish at the end.

Richard S. Bullitt
Reg. No. 30,733

Bayer Corporation
36 Columbia Road
Morristown, NJ 07962